| scholarly article | Q13442814 |
| P50 | author | J. Evan Sadler | Q42645712 |
| P2093 | author name string | B P Yawn | |
| R R Montgomery | |||
| A H James | |||
| T L Ortel | |||
| M J Manco-Johnson | |||
| M B Hultin | |||
| M E Rick | |||
| M Weinstein | |||
| W L Nichols | |||
| P2860 | cites work | Biochemistry and genetics of von Willebrand factor | Q22003890 |
| Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain | Q24304907 | ||
| Maternal age and fetal loss: population based register linkage study | Q24656936 | ||
| Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice | Q24685773 | ||
| Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation | Q28196402 | ||
| von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura | Q28239051 | ||
| Hemostatic drugs | Q28277099 | ||
| A novel family with recessive von Willebrand disease due to compound heterozygosity for a splice site mutation and a missense mutation in the von Willebrand factor gene | Q30688483 | ||
| Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data | Q30935344 | ||
| Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII | Q30981231 | ||
| Five-year follow-up of endometrial ablation: endometrial coagulation versus endometrial resection | Q31070898 | ||
| Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States | Q44763676 | ||
| Bleeding manifestations in males with von Willebrand disease | Q44763679 | ||
| A comparative in vitro evaluation of six von Willebrand factor concentrates | Q44845858 | ||
| Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). | Q44913450 | ||
| An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees | Q44958587 | ||
| Prevalence of von Willebrand disease in children: a multiethnic study | Q45090528 | ||
| Management of children with von Willebrand disease undergoing adenotonsillectomy | Q45099698 | ||
| The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders | Q45232803 | ||
| Quality control and factor VIII assays | Q45855109 | ||
| Females with von Willebrand disease: 72 years as the silent majority | Q45855121 | ||
| Recurrent haemoperitoneum in a female patient with type III von Willebrand's disease responded to administration of oral contraceptive | Q45855352 | ||
| Two consecutive pregnancies and deliveries in a patient with von Willebrand's disease type 3. | Q45856595 | ||
| Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience. | Q45856649 | ||
| Gene therapy. The strange case of chimeraplasty | Q45857182 | ||
| Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study | Q45857734 | ||
| Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. | Q45857746 | ||
| Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case–control study | Q45861577 | ||
| Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients | Q45862187 | ||
| von Willebrand disease and bleeding in women | Q45863706 | ||
| Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion | Q45863848 | ||
| Type 1 von Willebrand disease - a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history | Q45865552 | ||
| Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases | Q45867017 | ||
| Autosomal dominant type 1 von willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect | Q45867218 | ||
| Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey | Q45873269 | ||
| SSC/ISTH classification of hemophilia A: can hemophilia center laboratories achieve the new criteria? | Q45873383 | ||
| Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey | Q45873593 | ||
| Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease | Q45874158 | ||
| Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. | Q45874571 | ||
| Type 3 von Willebrand disease: assessment of complications and approaches to treatment -- results of a patient and Hemophilia Treatment Center Survey in the United States | Q45876357 | ||
| Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. | Q45877236 | ||
| Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing | Q45878918 | ||
| Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women | Q45882331 | ||
| Frequency of inherited bleeding disorders in women with menorrhagia | Q45885708 | ||
| Obstetric management in von Willebrand's disease: a report of 24 pregnancies and a reivesw of the literature | Q45886731 | ||
| Harmonisation of factor VIII:C assay results: study within the framework of the Dutch project 'Calibration 2000'. | Q45889356 | ||
| Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin | Q45889751 | ||
| DDAVP-induced hyponatremia in young children | Q46547512 | ||
| Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD-associated menorrhagia: a single-institution study | Q46596906 | ||
| The Prevalence of von Willebrand disease in women with abnormal uterine bleeding | Q46707469 | ||
| Cysteine-mutations in von Willebrand factor associated with increased clearance | Q46728073 | ||
| An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigrees | Q46892241 | ||
| Maternal and fetal outcomes in pregnancies affected by von Willebrand disease type 2. | Q46915075 | ||
| von Willebrand factor: measuring its antigen or function? Correlation between the level of antigen, activity, and multimer size using various detection systems | Q47283394 | ||
| DDAVP use during pregnancy: an analysis of its safety for mother and child | Q47850646 | ||
| Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family | Q48002948 | ||
| Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization | Q48377892 | ||
| Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. | Q50562220 | ||
| Secondary postpartum haemorrhage: incidence, morbidity and current management. | Q50683347 | ||
| The duration and character of postpartum bleeding among breast-feeding women. | Q50976904 | ||
| The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. | Q51958036 | ||
| Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. | Q53249298 | ||
| von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. | Q53327187 | ||
| Genetic determinants of hemostasis phenotypes in Spanish families. | Q54056926 | ||
| Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease | Q56426952 | ||
| First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene | Q56426953 | ||
| Significant linkage and non-linkage of type 1 von Willebrand disease to the von Willebrand factor gene | Q58184340 | ||
| Perioperative management of von Willebrand's disease in otolaryngologic surgery | Q32143654 | ||
| How I treat patients with von Willebrand disease | Q33336495 | ||
| Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). | Q33359536 | ||
| New concepts in von Willebrand disease | Q33364592 | ||
| Postoperative thrombocytopenia in type IIB von Willebrand disease | Q33403070 | ||
| Desmopressin and type II B von Willebrand disease | Q33432439 | ||
| Adenotonsillectomy in children with von Willebrand disease | Q33634802 | ||
| Haemophilia therapy: assessing the cumulative risk of HIV exposure by cryoprecipitate | Q33785725 | ||
| Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. | Q33815766 | ||
| DDAVP is not a panacea for children with bleeding disorders | Q33848513 | ||
| Molecular basis of human von Willebrand disease: analysis of platelet von Willebrand factor mRNA. | Q33857871 | ||
| Hereditary pseudohaemophilia | Q33870709 | ||
| Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract | Q33931597 | ||
| Interactions between von Willebrand factor and Factor VIII: where did they first meet | Q33948626 | ||
| High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. | Q33948828 | ||
| Acquired von Willebrand syndrome in aortic stenosis. | Q33967324 | ||
| Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor | Q33998293 | ||
| von Willebrand disease and pregnancy | Q34115850 | ||
| Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease | Q34202036 | ||
| The management of von Willebrand's disease-associated gastrointestinal angiodysplasia | Q34219131 | ||
| Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study | Q34278214 | ||
| The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. | Q34313804 | ||
| Treatment of von Willebrand's Disease | Q34340588 | ||
| von Willebrand disease: a common pediatric disorder | Q34367050 | ||
| A molecular approach to the classification of von Willebrand disease | Q34423469 | ||
| Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology | Q34423487 | ||
| Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function | Q34423491 | ||
| Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology | Q34423496 | ||
| Obstetric and gynaecological aspects of von Willebrand disease | Q34423502 | ||
| Female hormones and thrombosis | Q34521926 | ||
| The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study | Q34595035 | ||
| Laboratory diagnosis of congenital von Willebrand disease | Q34625946 | ||
| Microwave endometrial ablation versus endometrial resection: a randomized controlled trial | Q34674549 | ||
| von Willebrand's disease: an important cause of dysfunctional uterine bleeding | Q43933503 | ||
| Management of dental extractions in patients with bleeding disorders | Q43941732 | ||
| Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications | Q43981069 | ||
| Guidelines for the diagnosis and management of von Willebrand disease in Italy | Q44117199 | ||
| DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. | Q44201083 | ||
| Otolaryngologic surgery in children with von Willebrand disease | Q44247147 | ||
| Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction | Q44468499 | ||
| Platelet functional defects in women with unexplained menorrhagia | Q44518880 | ||
| Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? | Q44545077 | ||
| High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease | Q44546037 | ||
| Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium | Q44601232 | ||
| Measurement of von Willebrand factor activity: relative effects of ABO blood type and race | Q44604242 | ||
| Desmopressin (DDAVP) Responsiveness in Children With von Willebrand Disease | Q44649238 | ||
| Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study | Q44734148 | ||
| Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy | Q44747821 | ||
| Von Willebrand disease type 1: a diagnosis in search of a disease | Q34986170 | ||
| Acquired von Willebrand's syndrome: a single institution experience | Q35094919 | ||
| Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence. | Q35100545 | ||
| Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). | Q35181717 | ||
| Clinical practice. Combination estrogen-progestin oral contraceptives | Q35554350 | ||
| Risks of transfusion-transmitted infections: 2003. | Q35561964 | ||
| Shear stress and von Willebrand factor in health and disease | Q35590495 | ||
| Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process | Q35746598 | ||
| Testing for von Willebrand disease in women with menorrhagia: a systematic review. | Q35855066 | ||
| Endometrial ablation for von Willebrand disease-related menorrhagia--experience with seven cases | Q35882769 | ||
| von Willebrand disease in the developing world | Q36016019 | ||
| The safety of oral contraceptives: Epidemiologic insights from the first 30 years | Q36211903 | ||
| The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization | Q36533439 | ||
| External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program | Q36544691 | ||
| von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib | Q37255563 | ||
| Severe von Willebrand disease due to a defect at the level of von Willebrand factor mRNA expression: detection by exonic PCR-restriction fragment length polymorphism analysis. | Q37501127 | ||
| Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease | Q37662314 | ||
| Hyponatremia and seizures in young children given DDAVP. | Q38227774 | ||
| 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases | Q39433082 | ||
| Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group | Q39522420 | ||
| Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis | Q40442987 | ||
| DDAVP in Von Willebrand's disease: Repeated administration and the behaviour of the bleeding time | Q40707471 | ||
| Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins | Q40769949 | ||
| Haemoperitoneum caused by haemorrhagic corpus luteum in a patient with type 3 von Willebrand's disease | Q40830125 | ||
| Genetic induction of a releasable pool of factor VIII in human endothelial cells | Q40837627 | ||
| Management of abnormal uterine bleeding | Q40929439 | ||
| Failure to achieve gene conversion with chimeric circular oligonucleotides: potentially misleading PCR artifacts observed | Q40978297 | ||
| Hysterectomy after endometrial ablation | Q41297896 | ||
| Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand's disease in western Europe and Israel | Q41429947 | ||
| Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment | Q41681294 | ||
| Hepatitis viruses: genetic variants and clinical significance | Q41722708 | ||
| Thrombosis following desmopressin for uremic bleeding | Q42211970 | ||
| Intraoperative cerebral infarction after desmopressin administration in infant with end-stage renal disease | Q42565298 | ||
| Genetic heterogeneity of severe von Willebrand disease type III in the German population | Q42595743 | ||
| Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial | Q43484639 | ||
| Reduced von Willebrand factor survival in type Vicenza von Willebrand disease | Q43833411 | ||
| Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study | Q43847721 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diagnosis | Q16644043 |
| P304 | page(s) | 171-232 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Haemophilia | Q15753375 |
| P1476 | title | von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). | |
| P478 | volume | 14 |
| Q41095746 | "Bleeding in the jungle". |
| Q42134079 | 3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology. |
| Q55039568 | A case report on the successful perioperative management of hepatectomy for hepatocellular carcinoma in a patient with von Willebrand disease. |
| Q45050455 | A common VWF exon 28 haplotype in the Turkish population |
| Q35812405 | A cross-sectional study of bleeding phenotype in haemophilia A carriers |
| Q38840603 | A diagnostic approach to mild bleeding disorders |
| Q38772048 | A microfluidic model of hemostasis sensitive to platelet function and coagulation |
| Q46239492 | A novel use of thromboelastography in type 2B von Willebrand disease |
| Q92991250 | A personalized approach to the management of VWD |
| Q34909055 | A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease |
| Q45858911 | A prospective study of von Willebrand factor levels and bleeding in pregnant women with type 1 von Willebrand disease |
| Q92983692 | A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9 |
| Q45856018 | A single-centre study of haemostatic outcomes of joint replacement in von Willebrand disease and control patients and an analysis of the literature |
| Q35592188 | A two-center retrospective review of the hematologic evaluation and laboratory abnormalities in suspected victims of non-accidental injury |
| Q30443003 | ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia |
| Q88870817 | Abnormal Uterine Bleeding in Young Women with Blood Disorders |
| Q37480494 | Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. |
| Q90026927 | Acquired Von Willebrand Syndrome (AVWS) in cardiovascular disease: a state of the art review for clinicians |
| Q64094080 | Acquired von Willebrand Syndrome Associated with Cardiovascular Diseases |
| Q38260983 | Acquired von Willebrand syndrome in a child following Berlin Heart EXCOR Pediatric Ventricular Assist Device implantation: case report and concise literature review |
| Q45857162 | Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study. |
| Q37842356 | Advances in the diagnosis and management of type 1 von Willebrand disease |
| Q47350762 | Advances in the diagnosis and treatment of Von Willebrand disease |
| Q49989077 | Advances in the diagnosis and treatment of Von Willebrand disease. |
| Q29568910 | Allosteric activation of ADAMTS13 by von Willebrand factor. |
| Q34170382 | Analysis of the role of von Willebrand factor, platelet glycoprotein VI-, and α2β1-mediated collagen binding in thrombus formation |
| Q37091290 | Animal models of hemophilia and related bleeding disorders |
| Q38069965 | Approach to a child with bleeding in the emergency room. |
| Q45381927 | Approaches to investigating common bleeding disorders: an evaluation of North American coagulation laboratory practices |
| Q33383593 | Appropriate laboratory investigation in women with menorrhagia |
| Q88786608 | Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017 |
| Q45882932 | Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease |
| Q37994733 | Biological therapies for von Willebrand disease |
| Q92273594 | Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center |
| Q34133484 | Bleeding disorders in the tribe: result of consanguineous in breeding. |
| Q34224106 | Bleeding disorders, menorrhagia and iron deficiency: impacts on health-related quality of life |
| Q48344604 | Bleeding score in Type 1 von Willebrand disease patients using the ISTH-BAT questionnaire. |
| Q41353573 | Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric-specific bleeding |
| Q89776864 | Blood volume-based von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease |
| Q45874634 | Can you grow out of von Willebrand disease? |
| Q44211358 | Case studies in the management of refractory bleeding in patients with haemophilia A and inhibitors |
| Q36369902 | Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease |
| Q36317598 | Chitosan scaffold enhances growth factor release in wound healing in von Willebrand disease |
| Q45855353 | Classification of inherited von Willebrand disease and implications in clinical practice |
| Q99631223 | Classification of von Willebrand disease in the context of modern contemporary von Willebrand factor testing methodologies |
| Q41395304 | Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines |
| Q45868176 | Clinical and laboratory phenotype variability in type 2M von Willebrand disease |
| Q36920462 | Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States |
| Q44915387 | Clinical features and types of von Willebrand disease in Karachi |
| Q37552712 | Clinical features and types of von Willebrand disease in women with menorrhagia referred to hematology clinic of kermanshah |
| Q37778153 | Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause |
| Q34022444 | Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor |
| Q38650270 | Common gynecological challenges in adolescents with sickle cell disease |
| Q38616517 | Common skin and bleeding disorders that can potentially masquerade as child abuse |
| Q37259155 | Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease |
| Q33414729 | Complex haemostatic abnormalities as a cause of bleeding after neurosurgery in a patient with Gaucher disease |
| Q42995805 | Comprehensive treatment of periodontitis in patients with von Willebrand disease |
| Q39027754 | Congenital and acquired bleeding disorders in pregnancy. |
| Q45866496 | Congenital bleeding disorders in Karachi, Pakistan |
| Q37881998 | Consensus statement by hospital based dentists providing dental treatment for patients with inherited bleeding disorders |
| Q43239922 | Considerations for epidural anesthesia in a patient with type 1 von Willebrand disease |
| Q36166208 | Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis |
| Q38690381 | Controversies in the diagnosis of Type 1 von Willebrand disease |
| Q34758065 | Cost-consequence analysis of long-term prophylaxis in the treatment of von Willebrand disease in the Italian context |
| Q30555005 | Critical von Willebrand factor A1 domain residues influence type VI collagen binding |
| Q41620644 | Current and Emerging Options for the Management of Inherited von Willebrand Disease. |
| Q38900004 | Current and emerging approaches for assessing von Willebrand disease in 2016. |
| Q90670328 | Current approaches to diagnostic testing in von Willebrand Disease |
| Q48545948 | Current challenges in the diagnosis and management of patients with inherited von Willebrand 's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis |
| Q26796446 | Current controversies in the diagnosis and management of von Willebrand disease |
| Q57095004 | Current issues in diagnosis and treatment of von Willebrand disease |
| Q38020749 | Current management of patients with severe von Willebrand disease type 3: a 2012 update |
| Q34341172 | Current therapy in children and adolescents with von Willebrand disease |
| Q90628838 | Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding |
| Q24187266 | Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders |
| Q24197962 | Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders |
| Q24200542 | Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders |
| Q88172491 | Desmopressin stimulation testing: Response to intravenous and intranasal forms |
| Q45882736 | Developing a multidisciplinary Young Women's Blood Disorders Program: a single-centre approach with guidance for other centres |
| Q39027896 | Diagnosing von Willebrand disease: genetic analysis |
| Q33608224 | Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders |
| Q45869548 | Diagnosis and management of patients with von Willebrand's disease in Italy: an Expert Meeting Report |
| Q37892647 | Diagnosis and management of women with bleeding disorders--international guidelines and consensus from an international expert panel |
| Q35220634 | Diagnostic approach to von Willebrand disease |
| Q45862885 | Diagnostic challenges in patients with bleeding phenotype and von Willebrand exon 28 polymorphism p.D1472H. |
| Q45873187 | Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease |
| Q39062739 | Efficacy and safety of a VWF/FVIII concentrate (wilate® ) in inherited von Willebrand disease patients undergoing surgical procedures |
| Q33442035 | Enhanced Local Disorder in a Clinically Elusive von Willebrand Factor Provokes High-Affinity Platelet Clumping |
| Q43119328 | Enzymes that hydrolyze adenine nucleotides in platelets and polymorphisms in the alpha2 gene of integrin alpha2beta1 in patients with von Willebrand disease |
| Q90029345 | Evaluation and management of heavy menstrual bleeding in adolescents: the role of the hematologist |
| Q47416217 | Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels |
| Q35541233 | Evaluation of bleeding disorders in women with menorrhagia: a survey of obstetrician-gynecologists |
| Q54528863 | FVIII/VWF ratio is not a reliable predictor of VWD in children. |
| Q42948793 | Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival |
| Q35771219 | Females with FVIII and FIX deficiency have reduced joint range of motion |
| Q28081911 | Gene therapy for hemophilia |
| Q91675224 | Genetic regulation of plasma von Willebrand factor levels in health and disease |
| Q37351431 | Genome-wide association studies identify genetic loci for low von Willebrand factor levels |
| Q45883185 | Guidelines for bleeding disorders in women |
| Q34429179 | Haemophilia A carriers demonstrate pathological and radiological evidence of structural joint changes |
| Q36202662 | Haemophilia A carriers experience reduced health-related quality of life |
| Q37894820 | Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements. |
| Q45871911 | Haemostasis prophylaxis using single dose desmopressin acetate and extended use epsilon aminocaproic acid for adenotonsillectomy in patients with type 1 von Willebrand disease |
| Q44154008 | Hemorrhagic congenital diseases: What can be the future of plasma-derived products against recombinants? |
| Q38119530 | How I manage heavy menstrual bleeding |
| Q93196766 | How I manage severe von Willebrand disease |
| Q37097089 | How I treat patients with inherited bleeding disorders who need anticoagulant therapy |
| Q26750402 | Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data |
| Q42642393 | Hypertrophic obstructive cardiomyopathy, acquired von Willebrand syndrome, and gastrointestinal bleeding |
| Q34616043 | Hypertrophic obstructive cardiomyopathy, bleeding history, and acquired von Willebrand syndrome: response to septal myectomy |
| Q36411195 | Impact of diagnosis of von Willebrand disease on patient outcomes: Analysis of medical insurance claims data. |
| Q38088277 | Improving blood disorder diagnosis: reflections on the challenges. |
| Q37599008 | Indexes of von Willebrand factor as biomarkers of aortic stenosis severity (from the Biomarkers of Aortic Stenosis Severity [BASS] study) |
| Q91666685 | Inherited Bleeding Disorders in Iraq and Consanguineous Marriage |
| Q38326080 | Interaction between VWF and FVIII in treating VWD. |
| Q47549094 | Is gingival bleeding a symptom of type 2 and 3 von Willebrand disease? |
| Q40341489 | Joint surgery in von Willebrand disease: a multicentre cross-sectional study. |
| Q47957569 | Laboratory Testing for von Willebrand Factor Antigen (VWF:Ag). |
| Q47957561 | Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB). |
| Q47957551 | Laboratory Testing for von Willebrand Factor Ristocetin Cofactor (VWF:RCo). |
| Q47957540 | Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD). |
| Q38481908 | Laboratory diagnosis of von Willebrand disease. |
| Q57180921 | Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas |
| Q39098430 | Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease |
| Q37576572 | Laboratory testing for von Willebrand disease: toward a mechanism-based classification |
| Q37300927 | Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function |
| Q34319603 | Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association |
| Q92438600 | Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy |
| Q97551370 | Low VWF: insights into pathogenesis, diagnosis, and clinical management |
| Q38066864 | Making a diagnosis of VWD. |
| Q21092902 | Management of bleeding and coagulopathy following major trauma: an updated European guideline |
| Q35403273 | Microvascular abnormalities in patients with early systemic sclerosis: less severe morphological changes than in patients with definite disease |
| Q39144977 | Molecular diagnosis of von Willebrand disease. |
| Q39027900 | New treatment approaches to von Willebrand disease. |
| Q36085620 | Newer agents in antiplatelet therapy: a review |
| Q36814657 | No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation |
| Q45884066 | No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study |
| Q47793791 | Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels |
| Q37799156 | Obstetric Management of Adolescents with Bleeding Disorders |
| Q90307753 | One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients |
| Q45867884 | Oral health in adult patients with congenital coagulation disorders--a case control study |
| Q44110513 | Orthopaedic surgery in patients with von Willebrand disease |
| Q38897517 | Outcomes in Patients With Hemophilia and von Willebrand Disease Undergoing Invasive or Surgical Procedures. |
| Q47664550 | Outgrowing the laboratory diagnosis of type 1 von Willebrand disease: A two decade study. |
| Q30245691 | Pediatric Acquired von Willebrand Disease With Berlin Heart Excor Ventricular Assist Device Support. |
| Q37703427 | Perils, problems, and progress in laboratory diagnosis of von Willebrand disease |
| Q89564154 | Perioperative management of a pediatric patient with suspected type 1 von Willebrand disease undergoing tonsillectomy: a case report |
| Q49752171 | Pharmacokinetics-based clinical management of acquired von Willebrand syndrome: a case report |
| Q85651166 | Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A |
| Q53226592 | Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. |
| Q38088422 | Pitfalls in special coagulation testing: three illustrative case studies |
| Q38414457 | Plasma von Willebrand factor multimer quantitative analysis by in-gel immunostaining and infrared fluorescent imaging |
| Q45873770 | Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year 'real-world' experience |
| Q37273226 | Platelet interaction with von Willebrand factor is enhanced by shear-induced clustering of glycoprotein Ibα. |
| Q38413638 | Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. |
| Q35536246 | Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies |
| Q89538765 | Potential Undiagnosed VWD Or Other Mucocutaneous Bleeding Disorder Cases Estimated From Private Medical Insurance Claims |
| Q33424718 | Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: a European survey. |
| Q38862777 | Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey. |
| Q48357890 | Preanalytical issues that may cause misdiagnosis in haemophilia and von Willebrand disease. |
| Q45870427 | Predictors of von Willebrand disease diagnosis in individuals with borderline von Willebrand factor plasma levels |
| Q57824750 | Preoperative screening for bleeding disorders: A comprehensive laboratory assessment of clinical practice |
| Q30248782 | Present day management of inherited bleeding disorders in pregnancy |
| Q45875471 | Preventing postpartum haemorrhage-when guidelines fall short |
| Q36805813 | Principles of care for the diagnosis and treatment of von Willebrand disease |
| Q35006603 | Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency |
| Q35825745 | Providing young women with credible health information about bleeding disorders |
| Q52951456 | Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. |
| Q34183076 | Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals |
| Q44604269 | Quantitative impact of using different criteria for the laboratory diagnosis of type 1 von Willebrand disease |
| Q36920458 | Rapid discrimination of the phenotypic variants of von Willebrand disease. |
| Q57300553 | Rare forms of von Willebrand disease |
| Q30491320 | Recombinant von Willebrand factor for severe gastrointestinal bleeding unresponsive to other treatments in a patient with type 2A von Willebrand disease: a case report |
| Q36515685 | Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. |
| Q34492729 | Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period |
| Q64886128 | Recurrent Gastrointestinal Bleeding from Dieulafoy's Lesions in a Patient with Type 1 von Willebrand Disease: A Rare Association. |
| Q64137939 | Relevance of Abusive Head Trauma to Intracranial Hemorrhages and Bleeding Disorders |
| Q45871507 | Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model |
| Q45970222 | Rituximab effectiveness in a patient with juvenile systemic lupus erythematosus complicated with acquired Von Willebrand syndrome. |
| Q45868419 | Screening for von Willebrand disease in children: a case-control study |
| Q38970371 | Screening of female family members of von Willebrand disease patients: utility of a modified screening tool in a high-risk population |
| Q33620978 | Semantic prioritization of novel causative genomic variants |
| Q48518084 | Sensitive and specific assessment of recombinant von Willebrand factor in platelet function analyzer |
| Q59700235 | Significant gynecological bleeding in women with low von Willebrand factor levels |
| Q35985208 | Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A |
| Q33396445 | Spinal and epidural anesthesia in patients with hemorrhagic diathesis : decisions on the brink of minimum evidence? |
| Q30249030 | State of the art: von Willebrand disease. |
| Q35563446 | Successful aortic aneurysm repair in a woman with severe von Willebrand (type 3) disease |
| Q33392975 | Targeting von Willebrand factor and platelet glycoprotein Ib receptor |
| Q38058760 | Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk |
| Q38205952 | Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges. |
| Q37043558 | The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels |
| Q27339343 | The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition |
| Q45876026 | The Platelet Function Analyser (PFA)-100 and von Willebrand disease: a story well over 16 years in the making |
| Q88356526 | The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis |
| Q45730907 | The influence of the ABO blood type on the distribution of von Willebrand factor in healthy children with no bleeding symptoms |
| Q26996413 | The molecular characterization of von Willebrand disease: good in parts |
| Q36636312 | The role of the anesthesiologist in the care of the pregnant woman with Von Willebrand Disease |
| Q33442126 | The use of antifibrinolytics in pediatric patients with hypoproliferative thrombocytopenia |
| Q26748376 | Towards personalised therapy for von Willebrand disease: a future role for recombinant products |
| Q37602563 | Translational medicine advances in von Willebrand disease |
| Q45880195 | Treatment of Hodgkin's lymphoma in a patient with type III von Willebrand's disease |
| Q35683876 | Treatment of patients with von Willebrand disease |
| Q38636087 | Treatment of the acquired von Willebrand syndrome |
| Q39876587 | Type 2M von Willebrand disease - more often misidentified than correctly identified |
| Q43662496 | US Hemophilia Treatment Center population trends 1990-2010: patient diagnoses, demographics, health services utilization |
| Q37528592 | Unnecessary Hysterectomy due to Menorrhagia and Disorders of Hemostasis: An Example of Overuse and Excessive Demand for Medical Services |
| Q37107274 | Update on inherited disorders of haemostasis and pregnancy |
| Q92695321 | Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy |
| Q36357598 | Utility of a Paediatric Bleeding Questionnaire as a screening tool for von Willebrand disease in apparently healthy children |
| Q35846930 | Utility of a high VWF: FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice |
| Q49130346 | Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease |
| Q36944971 | Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease |
| Q38953180 | Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery |
| Q43220603 | Von Willebrand disease : diagnosis and management |
| Q37253917 | Von Willebrand disease in the United States: a perspective from Wisconsin |
| Q57094780 | Von Willebrand disease in the United States: perspective from the Zimmerman program |
| Q58781583 | Von Willebrand disease in the elderly: clinical perspectives |
| Q40329972 | Von Willebrand disease in the emergency department |
| Q28742241 | Von Willebrand disease: an overview |
| Q86244786 | Von Willebrand disease: pathogenesis and management |
| Q36922153 | Von Willebrand factor for menorrhagia: a survey and literature review |
| Q90480503 | Von Willebrand factor multimer quantitation for assessment of cardiac lesion severity and bleeding risk |
| Q30240214 | What have we learned from large population studies of von Willebrand disease? |
| Q54975780 | Why Do Patients Bleed? |
| Q90465278 | Women and inherited bleeding disorders - A review with a focus on key challenges for 2019 |
| Q83443434 | [Hierarchy for diagnostic and etiological management in menometrorrhagia] |
| Q83672337 | [The significance of bleeding disorders in patients with epistaxis] |
| Q42863476 | von Willebrand Disease in the Pediatric and Adolescent Population |
| Q34546675 | von Willebrand Disease. |
| Q45868270 | von Willebrand disease Outreach into Integrated Care Education (VOICE): a call to action. |
| Q53150022 | von Willebrand disease type1/type 2N compound heterozygotes: diagnostic and management challenges. |
| Q55053921 | von Willebrand disease. |
| Q45870652 | von Willebrand disease: a clinical and laboratory study of sixty-five patients |
| Q26863636 | von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies |
| Q92627004 | von Willebrand factor binding to myosin assists in coagulation |
| Q37376222 | von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. |
| Q45869687 | von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease |
| Q34223268 | von Willebrand's disease: a report from a meeting in the Åland islands |
Search more.